Clinical trials: Multiple Dose
Obesity
Phase 1 Study of NGM313 in Healthy Adult Participants
The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.
- Trial name
- NCT02708576
- Testing
- NGM313
- Where
- Australia
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Healthy
Study Evaluating a Combined Administration of Lecozotan SR and Citalopram in Young Healthy Subjects
To assess the safety and tolerability of lecozotan SR and citalopram when coadministred to healthy subjects.
- Trial name
- NCT00538889
- Testing
- Lecozotan SR, Citalopram
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy Volunteers
ANG-3070 in Healthy Adult Participants
This is a Phase 1 study, to assess the safety, tolerability, pharmacokinetics, and food effect of single and multiple ascending doses of ANG-3070 in healthy adult participants. This study is comprised of 12 cohorts.
- Trial name
- NCT04196179
- Testing
- ANG3070
- Where
- Australia
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Angion Biomedica Corp
Drug Interactions
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
- Trial name
- NCT05657613
- Testing
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Healthy
A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults
Part A of the study will test the safety, the amount of drug in the body, and effects of the drug in the body after multiple doses. This will be conducted in healthy overweight adults.
- Trial name
- B521MAD (NCT01707082)
- Testing
- PF-06282999, midazolam
- Where
- Belgium
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Pfizer
Endometriosis
Study on the Safety of the Drug BAY2395840 at Different Doses, the Way the Body Absorbs, Distributes and Excretes the Drug Including the Effect of Its Formulation (Tablet or Liquid) and the Effect of Food on the Absorption, Distribution or Excretion of the Drug in Healthy Male Participants
Researchers are looking for a better way to treat people who have endometriosis, a condition in which tissue similar to the lining of the uterus starts to grow in places outside of the uterus.
- Trial name
- NCT05517746
- Testing
- BAY2395840 tablet, BAY2395840 oral solution
- Where
- Germany
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Subjects
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
- Trial name
- NCT02509117
- Testing
- PF-06751979 single ascending dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Pfizer
Orthopoxviral Disease
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of two clinical doses of the anti-orthopoxvirus drug, ST-246, administered as a single daily oral dose for 14 days to healthy, fed volunteers.
- Trial name
- 246-Safety (NCT00907803)
- Testing
- ST-246 400 mg, ST-246 600 mg
- Where
- 3 sites in United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies
Dyslipidemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density…
- Trial name
- NCT05384262
- Testing
- AZD0780, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hyperuricemia
A Safety and Tolerability Study of FCN-207 in Healthy Volunteers
This research study is studying an investigational drug called FCN-207 in healthy adult males or females.
- Trial name
- NCT04622124
- Testing
- fasted vs. high-fat meal
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Inner Ear Disease
A Study of SENS 401 in Healthy Subjects
Sensorion are the study sponsor and the objective of this study is to investigate the safety and pharmacokinetic (PK) profile of SENS 401 in humans after a single and repeat dose administration and to confirm that, there is no…
- Trial name
- NCT03071003
- Testing
- SENS-401
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Simbec Research
Healthy
A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 765423 in healthy male subjects.
- Trial name
- NCT06232252
- Testing
- BI 765423
- Where
- Belgium
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of multiple oral doses of GMC-252-L-Lysine salt (GMC-252) in healthy subjects and type 2 diabetics.
- Trial name
- NCT02744820
- Testing
- GMC-252-L-Lysine Salt
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Genmedica Therapeutics S.L.
Cognitive Disorders
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of SUVN-D4010 in healthy male subjects following single or multiple ascending doses.
- Trial name
- NCT02575482
- Testing
- SUVN-D4010
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Healthy
A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers
The purpose of the study is to assess the effect of multiple oral doses of canagliflozin on a single oral dose of warfarin.
- Trial name
- NCT01195324
- Testing
- Canagliflozin/Warfarin
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Participants
A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants
The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants.
- Trial name
- NCT04882150
- Testing
- BMS-986196
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers
In accordance with International Conference on Harmonisation (ICH) E14 guidelines, this Phase I thorough QT (TQT) study will assess the arrhythmogenic potential of GFT505, by evaluating its effect on QT/QTc prolongation in…
- Trial name
- NCT02091310
- Testing
- GFT505, Moxifloxacin 400 mg
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Genfit
Pharmacokinetics
Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol
The clinical phase I study aims at investigating the conversion of the contraceptive compound norethisterone within the body towards the contraceptive compound ethinylestradiol.
- Trial name
- NCT02170038
- Testing
- Microgynon, Noristerat(BAY86-6308)
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
Primary Objective: To assess in healthy adult male subjects: The tolerability and safety of 21-day repeated subcutaneous (SC) doses of SAR425899 including two up titration steps.
- Trial name
- NCT02411825
- Testing
- SAR425899, metformin
- Where
- Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Inflammatory Diseases
Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512 from the blood, and to evaluate the…
- Trial name
- NCT00734240
- Testing
- ISIS 353512
- Where
- Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.